Navidea Biopharmaceuticals Short Interest Up 0.3% in August (NAVB)
Navidea Biopharmaceuticals (NYSE:NAVB) was the recipient of a significant growth in short interest in August. As of August 15th, there was short interest totalling 24,198,923 shares, a growth of 0.3% from the July 31st total of 24,116,182 shares, Analyst Ratings Net reports. Based on an average daily volume of 594,989 shares, the short-interest ratio is presently 40.7 days. Currently, 16.2% of the shares of the stock are sold short.
Shares of Navidea Biopharmaceuticals (NYSE:NAVB) opened at 1.28 on Wednesday. Navidea Biopharmaceuticals has a 1-year low of $1.11 and a 1-year high of $3.02. The stock has a 50-day moving average of $1.31 and a 200-day moving average of $1.61. The company’s market cap is $192.2 million.
Navidea Biopharmaceuticals, Inc (NYSE:NAVB), formerly Neoprobe Corporation, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.